Did Rectal Cancer Approval Just Shift AnaptysBio's (ANAB) Investment Narrative?

Simply Wall St.05:50

In October 2026, GSK received FDA approval for Jemperli, co-developed with AnaptysBio, as the first immunotherapy for adults with stage II and III MSI-H/dMMR locally advanced rectal cancer. The ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2679237153?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","is_english":true,"pubTime":"2026-10-30 05:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2679237153","market":"hk","top_or_hot":-1,"title":"Did Rectal Cancer Approval Just Shift AnaptysBio's (ANAB) Investment Narrative?","media":"Simply Wall St.","content":"<div>\n<p>In October 2026, GSK received FDA approval for Jemperli, co-developed with AnaptysBio, as the first immunotherapy for adults with stage II and III MSI-H/dMMR locally advanced rectal cancer. The ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-anab/anaptysbio/news/did-rectal-cancer-approval-just-shift-anaptysbios-anab-inves\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Did Rectal Cancer Approval Just Shift AnaptysBio's (ANAB) Investment Narrative?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDid Rectal Cancer Approval Just Shift AnaptysBio's (ANAB) Investment Narrative?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-30 05:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-anab/anaptysbio/news/did-rectal-cancer-approval-just-shift-anaptysbios-anab-inves><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In October 2026, GSK received FDA approval for Jemperli, co-developed with AnaptysBio, as the first immunotherapy for adults with stage II and III MSI-H/dMMR locally advanced rectal cancer. The ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-anab/anaptysbio/news/did-rectal-cancer-approval-just-shift-anaptysbios-anab-inves\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ANAB","symbol_name":"Anaptysbio Inc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-anab/anaptysbio/news/did-rectal-cancer-approval-just-shift-anaptysbios-anab-inves","article_id":"2679237153","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-anab/anaptysbio/news/did-rectal-cancer-approval-just-shift-anaptysbios-anab-inves","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2679237153","pubTimestamp":1793310653,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In October 2026, GSK received FDA approval for Jemperli, co-developed with AnaptysBio, as the first immunotherapy for adults with stage II and III MSI-H/dMMR locally advanced rectal cancer. The approval was supported by AZUR-1 data and was granted Fast Track, Breakthrough Therapy, Priority Review and a National Priority Voucher.\nThe AZUR-1 trial data suggest Jemperli monotherapy may allow a portion of MSI-H/dMMR rectal cancer patients to avoid surgery and its long term complications. This...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"ANAB":"Anaptysbio Inc","BK4139":"生物科技","FFTY":"Innovator IBD 50 ETF"},"translate_title":"直肠癌的批准是否改变了 AnaptysBio (ANAB) 的投资叙事？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FFTY":1.5,"ANAB":1.5},"content_text":"In October 2026, GSK received FDA approval for Jemperli, co-developed with AnaptysBio, as the first immunotherapy for adults with stage II and III MSI-H/dMMR locally advanced rectal cancer. The approval was supported by AZUR-1 data and was granted Fast Track, Breakthrough Therapy, Priority Review and a National Priority Voucher. The AZUR-1 trial data suggest Jemperli monotherapy may allow a portion of MSI-H/dMMR rectal cancer patients to avoid surgery and its long term complications. This could reshape how AnaptysBio-linked immunotherapy is used in this niche but clinically significant segment. Attention now turns to what this accelerated Jemperli approval, with its organ sparing potential, could mean for AnaptysBio's broader investment narrative.  Spot emerging oncology players benefiting from similar treatment shifts by screening for 36 healthcare AI stocks that are aligned with breakthroughs such as AnaptysBio's role in Jemperli.\nAdvertisementWhat Is AnaptysBio's Investment Narrative? To own AnaptysBio, you need to buy into a pretty focused story. This is a royalty driven biotech that depends heavily on its partners actually turning scientific wins into commercial traction. The fresh FDA approval for Jemperli in MSI H/dMMR rectal cancer reinforces that thesis. The drug is GSK’s to commercialize, but the success flows back to AnaptysBio through collaboration economics and royalties, which helped the business become profitable and generate US$352.7m of net income on US$106.1m of revenue. In the short term, the thesis leans on execution by partners rather than big internal commercial infrastructure, keeping capital intensity relatively low but putting more weight on deal quality and contract terms. Jemperli’s expanded label adds another potential royalty stream on top of what analysts already model, even though earnings are still forecast to edge down on average over the next three years and interest costs are not yet fully cushioned by recurring profits. Valuation screens flag AnaptysBio as “good value” on P/E and discounted cash flow, which is interesting if you accept that royalty driven earnings with high non cash elements will hold up, but there is a catch... There's only one way to know the right time to buy, sell or hold AnaptysBio. Head to Simply Wall St's company report for the latest analysis of AnaptysBio's Fair Value. NasdaqGS:ANAB 1-Year Stock Price Chart Exploring Other Perspectives Fair value estimates for AnaptysBio from the Simply Wall St Community span roughly US$87 to US$168 across three individual views. As a result, you are looking at a wide gap between the lowest and highest conviction. Those opinions were formed before the Jemperli approval news, so treat them as starting points and compare multiple viewpoints before committing capital. Explore 2 other AnaptysBio fair value estimates, including one that suggests it could be worth just $87.25! Decide For Yourself Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so consider relying on your own judgment.  A great starting point for your AnaptysBio research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision. See our latest analysis for AnaptysBio. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate AnaptysBio's overall financial health at a glance.  Looking For More Investment Ideas Beyond AnaptysBio? If the AnaptysBio story has sharpened your interest in targeted healthcare opportunities, it can help to scan a broader field of potential candidates with different risk and income profiles.  Prefer balance sheet strength and financial resilience as a starting point for your research? Then shortlist companies from the list of solid balance sheet and fundamentals (23 results). If you want potential mispricings backed by fundamentals, you can widen your watchlist using the 29 high quality undervalued stocks. For investors who care about steady income alongside capital appreciation potential, filter for income-focused opportunities with the 6 dividend fortresses.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2679237153","isCrawlerRequest":true}